<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">An Bras Dermatol</journal-id>
      <journal-id journal-id-type="iso-abbrev">An Bras Dermatol</journal-id>
      <journal-id journal-id-type="publisher-id">An Bras Dermatol</journal-id>
      <journal-title-group>
        <journal-title>Anais Brasileiros de Dermatologia</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0365-0596</issn>
      <issn pub-type="epub">1806-4841</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Dermatologia</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">23739718</article-id>
      <article-id pub-id-type="pmc">3750899</article-id>
      <article-id pub-id-type="doi">10.1590/S0365-05962013000200021</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Cutaneous leukocytoclastic vasculitis in the presence of
methimazole therapy<xref ref-type="fn" rid="fn01"><sup>*</sup></xref>
</article-title>
        <trans-title-group xml:lang="pt">
          <trans-title>Vasculite leucocitocl&#xE1;stica cut&#xE2;nea na vig&#xEA;ncia de terap&#xEA;utica com
metimazol</trans-title>
        </trans-title-group>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Ribeiro</surname>
            <given-names>Carla de Oliveira</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
          <xref ref-type="corresp" rid="c01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Magrin</surname>
            <given-names>Paula Ferrazzi</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Vilar</surname>
            <given-names>Eno&#xED; Aparecida Guedes</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Dur&#xE3;es</surname>
            <given-names>Sandra Maria Barbosa</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Estrella</surname>
            <given-names>Rog&#xE9;rio Ribeiro</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">3</xref>
        </contrib>
      </contrib-group>
      <aff id="aff1"><label>1</label> Postgraduate student in the Dermatology Department of the Ant&#xF4;nio Pedro
University Hospital - Universidade Federal Fluminense (HUAP-UFF) &#x2013; Niter&#xF3;i (RJ), Brazil </aff>
      <aff id="aff2"><label>2</label> PhD &#x2013; Associate Professor in the Pathology Department of the Ant&#xF4;nio
Pedro University Hospital - Universidade Federal Fluminense (HUAP-UFF) &#x2013; Niter&#xF3;i (RJ),
Brazil </aff>
      <aff id="aff3"><label>3</label> PhD &#x2013; Associate Professor of the Dermatology Department of the Ant&#xF4;nio
Pedro University Hospital - Universidade Federal Fluminense (HUAP-UFF) &#x2013; Niter&#xF3;i (RJ),
Brazil </aff>
      <author-notes>
        <corresp id="c01"><bold>Mailing address:</bold> Carla de Oliveira Ribeiro, - Rua Presidente Backer 54/
1601 - Icara&#xED; - Niteroi - Cep 24220-041, RJ - Brazil - E-mail:
<email>carla_ribb@yahoo.com.br</email></corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <season>Mar-Apr</season>
        <year>2013</year>
      </pub-date>
      <volume>88</volume>
      <issue>2</issue>
      <fpage>283</fpage>
      <lpage>286</lpage>
      <history>
        <date date-type="received">
          <day>09</day>
          <month>1</month>
          <year>2012</year>
        </date>
        <date date-type="accepted">
          <day>22</day>
          <month>2</month>
          <year>2012</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9;2013 by Anais Brasileiros de Dermatologia</copyright-statement>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">
          <license-p>This is an open-access article distributed under the terms of the Creative
Commons Attribution License, which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly
cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Treatment with antithyroid drugs may be accompanied by side effects. We present a
patient diagnosed with Grave's Disease who developed extensive vasculitis in the
lower limbs during methimazole use. After suspension of the methimazole and the
introduction of prednisone in immunesupressor doses the cutaneous lesions started to
involute.</p>
      </abstract>
      <trans-abstract xml:lang="pt">
        <p>A terap&#xEA;utica com drogas antitireoidianas pode ser acompanhada de efeitos colaterais.
Apresentamos um caso de paciente com diagn&#xF3;stico de Doen&#xE7;a de Graves que na vig&#xEA;ncia
da terap&#xEA;utica com metimazol desenvolveu um quadro extenso de vasculite de membros
inferiores. A partir da suspens&#xE3;o do metimazol e da introdu&#xE7;&#xE3;o de prednisona em doses
imunossupressoras as les&#xF5;es cut&#xE2;neas entraram em involu&#xE7;&#xE3;o.</p>
      </trans-abstract>
      <kwd-group>
        <kwd>Anti-neutrophil cytoplasmic antibody-associated vasculitis</kwd>
        <kwd>Methimazole</kwd>
        <kwd>Vasculitis</kwd>
        <kwd>Cutaneous leukocytoclastic vasculitis</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec>
      <title>INTRODUCTION</title>
      <p>The common therapy for Graves'Disease (GD) prescribes antithyroid drugs (ATD) such as
propilthiouracil (PTU) and methimazole (MTM). This therapy may cause a number of side
effects such as elevated liver enzymes, leukopenia, skin rash and arthralgia.<sup><xref ref-type="bibr" rid="r01">1</xref>-<xref ref-type="bibr" rid="r06">6</xref></sup>
</p>
      <p>Vasculitis diseases directly related to the use of ATD are considered to be a group of
systemic sicknesses with multiple cutaneous manifestations from erythema to necrosis and
histopathological features such as leukocytoclastic vasculitis with fibrinoid necrosis
of the vessel walls, in addition to neutrophils in the inflammatory infiltrate.<sup><xref ref-type="bibr" rid="r05">5</xref>,<xref ref-type="bibr" rid="r07">7</xref></sup>
</p>
      <p>Although the association between Vasculitis and MTM has been previously described its
frequency appears to be low when compared to the number of cases involving treatment
with PTU. <sup><xref ref-type="bibr" rid="r04">4</xref>-<xref ref-type="bibr" rid="r06">6</xref>,<xref ref-type="bibr" rid="r08">8</xref>,<xref ref-type="bibr" rid="r09">9</xref></sup>
</p>
    </sec>
    <sec>
      <title>CASE REPORT</title>
      <p>Female patient, 33-years-old, black, host to GD for over 6 years, using MTM since the
onset of symptoms. Patient was advised to seek dermatology assistance due to the
emergence of superficial skin lesions in the lower limbs over a period of 20 days,
associated with fever, joint pain and tremor of the extremities. The dermatological exam
exposed erythematous purpuric lesions on the dorsum of the feet and plantar cavus tense
blisters with hemorrhagic content in the malleolar region which spread to large necrotic
areas. (<xref ref-type="fig" rid="f01">Figures 1</xref>,<xref ref-type="fig" rid="f02">2</xref> and <xref ref-type="fig" rid="f03">3</xref>).</p>
      <fig id="f01" orientation="portrait" position="float">
        <label>FIGURE 1</label>
        <caption>
          <p>Erythematous purpuric lesions and blisters</p>
        </caption>
        <graphic xlink:href="abd-88-0283-g01"/>
      </fig>
      <fig id="f02" orientation="portrait" position="float">
        <label>FIGURE 2</label>
        <caption>
          <p>Purpuric lesions and blisters with hemorrhagic material</p>
        </caption>
        <graphic xlink:href="abd-88-0283-g02"/>
      </fig>
      <fig id="f03" orientation="portrait" position="float">
        <label>FIGURE 3</label>
        <caption>
          <p>Extensive necrotic areas</p>
        </caption>
        <graphic xlink:href="abd-88-0283-g03"/>
      </fig>
      <p>The chest x-ray and renal function tests failed to detect significant changes. The
absence of hematuria was also noted. Laboratory data is presented in <xref ref-type="table" rid="t01">table 1</xref></p>
      <table-wrap id="t01" orientation="portrait" position="float">
        <label>Table 1</label>
        <caption>
          <p>Laboratory data</p>
        </caption>
        <table frame="hsides" rules="groups">
          <thead>
            <tr>
              <td rowspan="1" colspan="1">
                <bold>Laboratory data</bold>
              </td>
              <td rowspan="1" colspan="1">
                <bold>Results</bold>
              </td>
              <td rowspan="1" colspan="1">
                <bold>Reference value</bold>
              </td>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td rowspan="1" colspan="1">TSH</td>
              <td rowspan="1" colspan="1">0,08 UI/ml</td>
              <td rowspan="1" colspan="1">0,4-6,0 UI/ml</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">
</td>
              <td rowspan="1" colspan="1">
</td>
              <td rowspan="1" colspan="1">
</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">T4</td>
              <td rowspan="1" colspan="1">2,82 ug/dl</td>
              <td rowspan="1" colspan="1">4,5-12,5 ug/dl</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">
</td>
              <td rowspan="1" colspan="1">
</td>
              <td rowspan="1" colspan="1">
</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Anti-TPO</td>
              <td rowspan="1" colspan="1">674,8 UI/ml</td>
              <td rowspan="1" colspan="1">&lt; 40 UI/ml- Negative, 40-100 UI/ml-Borderline, &gt;100 UI/ml-
Positive</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">
</td>
              <td rowspan="1" colspan="1">
</td>
              <td rowspan="1" colspan="1">
</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Anti-thyroglobulin</td>
              <td rowspan="1" colspan="1">21,8 UI/ml</td>
              <td rowspan="1" colspan="1">&lt;75 UI/ml- Negative, 75-100 UI/ml Borderline, &gt;100 UI/ml-
Positive</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">
</td>
              <td rowspan="1" colspan="1">
</td>
              <td rowspan="1" colspan="1">
</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">FAN</td>
              <td rowspan="1" colspan="1">Non reactive</td>
              <td rowspan="1" colspan="1">Non reactive</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">
</td>
              <td rowspan="1" colspan="1">
</td>
              <td rowspan="1" colspan="1">
</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">P-ANCA</td>
              <td rowspan="1" colspan="1">12 U/ml</td>
              <td rowspan="1" colspan="1">Positive&gt; 5 U/ml</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">
</td>
              <td rowspan="1" colspan="1">
</td>
              <td rowspan="1" colspan="1">
</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">C-ANCA</td>
              <td rowspan="1" colspan="1">Negative</td>
              <td rowspan="1" colspan="1">Positive&gt; 5 U/ml</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <p>A biopsy of the superficial skin lesion was in addition performed in the right lateral
malleolus region. Histopathological examination revealed neutrophilic leukocytoclastic
vasculitis of small vessels (<xref ref-type="fig" rid="f04">Figure 4</xref>).</p>
      <fig id="f04" orientation="portrait" position="float">
        <label>FIGURE 4</label>
        <caption>
          <p>Small vessels leukocytoclastic vasculitis</p>
        </caption>
        <graphic xlink:href="abd-88-0283-g04"/>
      </fig>
      <p>In view of the tests feedback, we decided to discontinue MTM and start therapy with
prednisone (1mg/kg). We were able to observe continuous improvement after 7 days (<xref ref-type="fig" rid="f05">Figure 5</xref>).</p>
      <fig id="f05" orientation="portrait" position="float">
        <label>FIGURE 5</label>
        <caption>
          <p>Regression of skin lesions</p>
        </caption>
        <graphic xlink:href="abd-88-0283-g05"/>
      </fig>
    </sec>
    <sec sec-type="discussion">
      <title>DISCUSSION</title>
      <p>ATD drugs can cause a number of systemic changes such as fever, rash, hives,
arthralgia/arthritis, sensorineural hearing loss, central nervous system vasculitis,
respiratory symptoms (from epistaxis to diffuse alveolar hemorrhage), scleritis,
glomerulonephritis, lupus-like syndrome, polychondritis, toxic hepatitis and
agranulocytosis. Adverse reactions occur in 1%-5% of patients using these drugs, often
with higher doses of MTM, while the use of PTU does not influence the onset of the
above-mentioned reactions.<sup><xref ref-type="bibr" rid="r01">1</xref>-<xref ref-type="bibr" rid="r04">4</xref>,<xref ref-type="bibr" rid="r06">6</xref>,<xref ref-type="bibr" rid="r07">7</xref>,<xref ref-type="bibr" rid="r09">9</xref></sup>
</p>
      <p>In a review of the literature by Cooper certain minor side effects were listed,
including dermatological, arthralgia and gastrointestinal tract changes which occurred
in approximately 5% of patients using these drugs, often the same for both. The same
author considered the following to be the most prominent side effects: arthritis,
positive vasculitis with anti-neutrophil cytoplasmic antibodies (ANCA), agranulocytosis,
autoimmune hepatitis, cholestasis, hypoglycemia, pancreatitis and hypoprothrombinemia.
<sup><xref ref-type="bibr" rid="r01">1</xref>-<xref ref-type="bibr" rid="r02">2</xref></sup>
</p>
      <p>Agranulocytosis is the worst side effect, occurring in 0.37% of the patients using PTU
(OCT) and 0.35% of patients treated with MTM. According to estimates hepatotoxicity can
also occur at a frequency of 0.1-0.2%.<sup><xref ref-type="bibr" rid="r01">1</xref>-<xref ref-type="bibr" rid="r02">2</xref></sup>
</p>
      <p>Vasculitis is the third main toxic reaction observed with the use of DAT, classically
associated to PTU therapy. <sup><xref ref-type="bibr" rid="r01">1</xref>-<xref ref-type="bibr" rid="r02">2</xref></sup> In 30% of cases of vasculitis triggered by these drugs skin disorders are
observed.<sup><xref ref-type="bibr" rid="r05">5</xref></sup> Dermatological manifestations and arthralgia are the most frequently observed
findings in these cases, while lungs and renal involvement occur less frequently,
usually in more serious cases. <sup><xref ref-type="bibr" rid="r05">5</xref>,<xref ref-type="bibr" rid="r07">7</xref>,<xref ref-type="bibr" rid="r09">9</xref></sup>
</p>
      <p>The pathogenesis of vasculitis associated with ATD is unknown. It was shown that PTU
might bind to myeloproxidade, altering its structure and leading to the formation of
auto antibodies. Another theory is that activated neutrophils produce increased amounts
of myeloperoxidase, converting the drugs into free radicals and thereby generating
vascular injury. It is also speculated that other factors may influence serum disease
activity such as positivity for antiendothelial cells.<sup><xref ref-type="bibr" rid="r01">1</xref>-<xref ref-type="bibr" rid="r02">2</xref>,<xref ref-type="bibr" rid="r05">5</xref></sup>
</p>
      <p>In cases where the ATD correlate ANCA-positive vasculitis, most of the literature
reports concern MPO-ANCA (or p-ANCA), especially in Asian patients using PTU.<sup><xref ref-type="bibr" rid="r05">5</xref></sup> The prevalence of MPO-ANCA in antithyroid drug users ranges from 25%-60% in
patients treated with PTU and from 3% - 4% in those treated with MTM.<sup><xref ref-type="bibr" rid="r03">3</xref>,<xref ref-type="bibr" rid="r05">5</xref>-<xref ref-type="bibr" rid="r06">6</xref>,<xref ref-type="bibr" rid="r08">8</xref>-<xref ref-type="bibr" rid="r09">9</xref></sup>
</p>
      <p>The first case of vasculitis associated with MTM was described in 1995 by Kawachi.<sup><xref ref-type="bibr" rid="r10">10</xref></sup> Fever, rash, arthralgia, hepatitis and agranulocytosis are also described as
side effects of this drug.<sup><xref ref-type="bibr" rid="r01">1</xref>-<xref ref-type="bibr" rid="r04">4</xref>,<xref ref-type="bibr" rid="r06">6</xref>,<xref ref-type="bibr" rid="r09">9</xref></sup> In their 1999 publication Gunton et al assembled 27 cases of ATD-induced
vasculitis with positive ANCA in which only one case was related to MTM.<sup><xref ref-type="bibr" rid="r04">4</xref></sup> In our study case we observed some unique details such as p-ANCA positivity and
the absence of signs of systemic disorders (only fever, arthralgia, tremor of the
extremities), which lends credence to the possibility that this type of vasculitis has a
clinical spectrum.</p>
      <p>With regard to ANCA, key serological markers can be observed in cases of small vessel
vasculitis. These consist of autoantibodies directed to the lysosomal enzymes of
neutrophils that can be divided by indirect immunofluorescence into two main groups:
cytoplasmic (c-ANCA) that reacts against proteinase 3, and perinuclear (p-ANCA) that
reacts against myeloperoxidase. ANCA-specific for proteinase 3 and myeloperoxidase is
associated with necrotizing vasculitis, especially Wegener's granulomatosis, microscopic
polyangiitis (MPA) and idiopathic crescentic glomerulonephritis.<sup><xref ref-type="bibr" rid="r01">1</xref>,<xref ref-type="bibr" rid="r05">5</xref>,<xref ref-type="bibr" rid="r07">7</xref></sup>
</p>
      <p>Vasculitis associated with MTM is a rare complication, with few cases described in the
medical literature. It may in due course affect various organs such as lungs and
kidneys, but few reports exist of a lethal outcome.</p>
      <p>Early recognition of cutaneous vasculitis is crucial because drug withdrawal should be
immediate in order to prevent the progression of the disease and its systemic
complications. The use of steroids in extensive cases is needed to bring about a
favorable outcome.</p>
      <p>In the case described, the resolution of skin lesions after ATD was discontinued and
following brief treatment with corticosteroids (in addition to the exclusion of other
ethiologies, combined with the histological pattern found) strengthen the diagnosis of
vasculitis associated with the use of MTM.</p>
      <p>Few reports in the literature link the presence of ANCA and vasculitis in patients using
MTM. Further studies are needed to elucidate the pathogenesis of vasculitis.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn id="fn01" fn-type="other">
        <p>* Study conducted in the Dermatology Department of the Ant&#xF4;nio Pedro University
Hospital - Universidade Federal Fluminense (HUAP-UFF) - Niter&#xF3;i (RJ), Brazil.</p>
      </fn>
      <fn id="fn02" fn-type="conflict">
        <p>Conflict of interest: None</p>
      </fn>
      <fn id="fn03" fn-type="financial-disclosure">
        <p>Financial funding: None</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>REFERENCES</title>
      <ref id="r01">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cooper</surname>
              <given-names>DS</given-names>
            </name>
          </person-group>
          <article-title>Antithyroid drugs</article-title>
          <source>N Engl J Med</source>
          <year>2005</year>
          <volume>352</volume>
          <fpage>905</fpage>
          <lpage>917</lpage>
          <pub-id pub-id-type="pmid">15745981</pub-id>
        </element-citation>
      </ref>
      <ref id="r02">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ahmed</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Rao</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Simha</surname>
              <given-names>V</given-names>
            </name>
          </person-group>
          <article-title>Antineutrophil cytoplasmic antibody-positive vasculitis
in a patient with Grave&#xB4;s Disease: cross-reaction between propylthiouracil and
methimazole</article-title>
          <source>Endocr Pract</source>
          <year>2010</year>
          <volume>16</volume>
          <fpage>449</fpage>
          <lpage>451</lpage>
          <pub-id pub-id-type="pmid">20061292</pub-id>
        </element-citation>
      </ref>
      <ref id="r03">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gum&#xE0;</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Salinas</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Reverter</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Roca</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Valls-Roc</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Juan</surname>
              <given-names>M</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Frequency of antineutrophil cytoplasmic antibody in
Graves' Disease patients treated with methimazole</article-title>
          <source>J Clin Endocrinol Metab</source>
          <year>2003</year>
          <volume>88</volume>
          <fpage>2141</fpage>
          <lpage>2146</lpage>
          <pub-id pub-id-type="pmid">12727967</pub-id>
        </element-citation>
      </ref>
      <ref id="r04">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gunton</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Stiel</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Caterson</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>McElduff</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Clinical case seminar: anti-thyroid drugs and
antineutrophil cytoplasmic antibody positive vasculitis. A case report and review
of the literature</article-title>
          <source>J Clin Endocrinol Metab</source>
          <year>1999</year>
          <volume>84</volume>
          <fpage>13</fpage>
          <lpage>16</lpage>
          <pub-id pub-id-type="pmid">9920055</pub-id>
        </element-citation>
      </ref>
      <ref id="r05">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pietszkowski</surname>
              <given-names>NC</given-names>
            </name>
            <name>
              <surname>Carvalho</surname>
              <given-names>GA</given-names>
            </name>
            <name>
              <surname>Souza</surname>
              <given-names>HN</given-names>
            </name>
            <name>
              <surname>Werka</surname>
              <given-names>CR Jr</given-names>
            </name>
            <name>
              <surname>Borazo</surname>
              <given-names>LA</given-names>
            </name>
            <name>
              <surname>Graf</surname>
              <given-names>H</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Antineutrophil cytoplasmic antibody (Anca)-associated
autoimmune disease induced by propylthiouracil</article-title>
          <source xml:lang="pt">Arq Bras Endocrinol Metab</source>
          <year>2007</year>
          <volume>51</volume>
          <fpage>136</fpage>
          <lpage>141</lpage>
        </element-citation>
      </ref>
      <ref id="r06">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Thong</surname>
              <given-names>HY</given-names>
            </name>
            <name>
              <surname>Chu</surname>
              <given-names>CY</given-names>
            </name>
            <name>
              <surname>Chiu</surname>
              <given-names>HC</given-names>
            </name>
          </person-group>
          <article-title>Methimazole-induced antineutrophil cytoplasmic antibody
(ANCA)-associated vasculitis and lupus-like syndrome with a cutaneous feature of
vesiculo-bullous systemic lupus erythematosus</article-title>
          <source>Acta Derm Venereol</source>
          <year>2002</year>
          <volume>82</volume>
          <fpage>206</fpage>
          <lpage>208</lpage>
          <pub-id pub-id-type="pmid">12353714</pub-id>
        </element-citation>
      </ref>
      <ref id="r07">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Brandt</surname>
              <given-names>HRC</given-names>
            </name>
            <name>
              <surname>Arnone</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Valente</surname>
              <given-names>NYS</given-names>
            </name>
            <name>
              <surname>Criado</surname>
              <given-names>PR</given-names>
            </name>
            <name>
              <surname>Sotto</surname>
              <given-names>MN</given-names>
            </name>
          </person-group>
          <article-title xml:lang="pt">Vasculite cut&#xE2;nea de pequenos vasos: etiologia,
patog&#xEA;nese, classifica&#xE7;&#xE3;o e crit&#xE9;rios diagn&#xF3;sticos -Parte I</article-title>
          <source xml:lang="pt">An Bras Dermatol</source>
          <year>2007</year>
          <volume>82</volume>
          <fpage>387</fpage>
          <lpage>406</lpage>
        </element-citation>
      </ref>
      <ref id="r08">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Martin</surname>
              <given-names>DB</given-names>
            </name>
            <name>
              <surname>Deng</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Gaspari</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Pearson</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Perinuclear Antineutrophil Cytoplasmic Antibody-
Associated Vasculitis in a Patient with Graves' Disease treated with
Methimazole</article-title>
          <source>Skinmed</source>
          <year>2006</year>
          <volume>5</volume>
          <fpage>302</fpage>
          <lpage>305</lpage>
          <pub-id pub-id-type="pmid">17086001</pub-id>
        </element-citation>
      </ref>
      <ref id="r09">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rodrigues</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Jorge</surname>
              <given-names>PT</given-names>
            </name>
          </person-group>
          <article-title xml:lang="pt">Vasculite leucocitocl&#xE1;stica: uma rara manifesta&#xE7;&#xE3;o
associada ao metimazol</article-title>
          <source xml:lang="pt">Arq Bras Endocrinol Metab</source>
          <year>2002</year>
          <volume>46</volume>
          <fpage>716</fpage>
          <lpage>9</lpage>
        </element-citation>
      </ref>
      <ref id="r10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lau</surname>
              <given-names>EY</given-names>
            </name>
            <name>
              <surname>Song</surname>
              <given-names>SY</given-names>
            </name>
            <name>
              <surname>Chan</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Kwok</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Ma</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Kung</surname>
              <given-names>AW</given-names>
            </name>
          </person-group>
          <article-title>Methimazole-induced antineutrophil cytoplasmic
antibody-associated diffuse alveolar haemorrhage in a Chinese woman with Graves'
Disease</article-title>
          <source>Hong Kong Med J</source>
          <year>2009</year>
          <volume>15</volume>
          <fpage>209</fpage>
          <lpage>212</lpage>
          <pub-id pub-id-type="pmid">19494377</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
